The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Antibody–Drug Conjugates: The Last Decade
Open accessAbstract
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Self-citationInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838 · cited 1×
“To circumvent the lack of intracellular bacteria targeting associated with actual treatments, Genentech decided to develop an antibody–antibiotic conjugate (AAC), designed with a carefully selected antibody, linker and antibiotic, to achieve better activity than vancomycin for the treatment of bacteremia in vivo [124,…”
BackgroundTargeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J. M., Bezabeh, B. Z., Fleming, R. L., Dimasi, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.008 · Cited by 397
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Katz, J., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368
Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 340
Ricart, A. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0486 · Cited by 332
Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811224 · Cited by 322
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
Badescu, G., Bryant, P., Bird, M., Henseleit, K., Swierkosz, J., Parekh, V., Tommasi, R., Pawlisz, E., Jurlewicz, K., Farys, M., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500148x · Cited by 290
Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0862 · Cited by 278
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 277
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Mantaj, J., Jackson, P. J. M., Rahman, K. M., & Thurston, D. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201510610 · Cited by 262
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
Adams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., & Weiner, L. M. (1993) · PubMed · Cited by 248
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Elgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W. M. P. B., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., van den Dobbelsteen, D. J., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500781a · Cited by 221
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 213
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Erickson, H. K., Lewis Phillips, G. D., Leipold, D. D., Provenzano, C. A., Mai, E., Johnson, H. A., Gunter, B., Audette, C. A., Gupta, M., Pinkas, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0727 · Cited by 194
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 189
Targeting B-Cell Maturation Antigen in Multiple Myeloma
Tai, Y.-T., & Anderson, K. C. (2015) · Immunotherapy · doi:10.2217/imt.15.77 · Cited by 188
Massa, S., Xavier, C., De Vos, J., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500111t · Cited by 184
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Phillips, A. C., Boghaert, E. R., Vaidya, K. S., Mitten, M. J., Norvell, S., Falls, H. D., DeVries, P. J., Cheng, D., Meulbroek, J. A., Buchanan, F. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0901 · Cited by 180
Schumacher, F. F., Nunes, J. P. M., Maruani, A., Chudasama, V., Smith, M. E. B., Chester, K. A., Baker, J. R., & Caddick, S. (2014) · Org. Biomol. Chem. · doi:10.1039/c4ob01550a · Cited by 175
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Yu, S.-F., Zheng, B., Go, M., Lau, J., Spencer, S., Raab, H., Soriano, R., Jhunjhunwala, S., Cohen, R., Caruso, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2035 · Cited by 168
Behrens, C. R., Ha, E. H., Chinn, L. L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., Liao-Chan, S., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00432 · Cited by 162
Pfeifer, M., Zheng, B., Erdmann, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.48 · Cited by 152
Graversen, J. H., Svendsen, P., Dagnæs‐Hansen, F., Dal, J., Anton, G., Etzerodt, A., Petersen, M. D., Christensen, P. A., Møller, H. J., & Moestrup, S. K. (2012) · Molecular Therapy · doi:10.1038/mt.2012.103 · Cited by 150
Hamblett, K. J., Jacob, A. P., Gurgel, J. L., Tometsko, M. E., Rock, B. M., Patel, S. K., Milburn, R. R., Siu, S., Ragan, S. P., Rock, D. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1610 · Cited by 150
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
van den Bent, M. J., Gan, H. K., Lassman, A. B., Kumthekar, P., Merrell, R. T., Butowski, N. A., Lwin, Z., Mikkelsen, T., Nabors, B., Papadopoulos, K. P., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3451-1 · Cited by 139
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Ponte, J. F., Ab, O., Lanieri, L., Lee, J., Coccia, J. A., Bartle, L. M., Themeles, M., Zhou, Y., Pinkas, J., & Ruiz‐Soto, R. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.002 · Cited by 127
Nunes, J. P. M., Morais, M., Vassileva, V., Robinson, E., Rajkumar, V. S., Smith, M. E. B., Pedley, R. B., Caddick, S., Baker, J. R., & Chudasama, V. (2015) · Chemical Communications · doi:10.1039/c5cc03557k · Cited by 121
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R., Isakoff, S. J., Starodub, A., Shah, N. C., O’Shaughnessy, J., Kalinsky, K. M., Guarino, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297.2017.2.test · Cited by 119
Amanitins and their development as a payload for antibody-drug conjugates
Pahl, A. M., Lutz, C., & Hechler, T. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.08.005 · Cited by 118
Cancer stromal targeting (CAST) therapy
Matsumura, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.010 · Cited by 113
Kahl, B. S., Hamadani, M., Radford, J. A., Carlo‐Stella, C., Caimi, P. F., Reid, E. G., Feingold, J. M., Ardeshna, K. M., Solh, M., Heffner, L. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0711 · Cited by 111
An Immunosuppressive Antibody–Drug Conjugate
Wang, R. E., Liu, T., Wang, Y., Cao, Y. J., Du, J., Luo, X., Deshmukh, V. A., Kim, C. H., Lawson, B. R., Tremblay, M. S., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00620 · Cited by 110
Beck, A., Terral, G., Debaene, F., Wagner‐Rousset, E., Marcoux, J., Janin-Bussat, M.-C., Colas, O., DORSSELAER, A. V., & Cianférani, S. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2016.1132167 · Cited by 109
Self-citationFaltas, B. M., Goldenberg, D. M., Ocean, A. J., Govindan, S. V., Wilhelm, F. E., Sharkey, R. M., Hajdenberg, J. J., Hodes, G., Nanus, D. M., & Tagawa, S. T. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.10.002 · Cited by 106
Nagayama, A., Ellisen, L. W., Chabner, B. A., & Bardia, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0535-0 · Cited by 103
A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
Zhao, H., Gulesserian, S., Malinao, M. C., Ganesan, S. K., Song, J., Chang, M. S., Williams, M. M., Zeng, Z., Mattie, M. D., Mendelsohn, B. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0133 · Cited by 97
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain, M. P., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B. M., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 94
Beck, A., D’Atri, V., Ehkirch, A., Fekete, S., Hernandez‐Alba, O., Gahoual, R., Leize‐Wagner, E., François, Y., Guillarme, D., & Cianférani, S. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1578215 · Cited by 94
Self-citationCorso, A. D., Cazzamalli, S., Gébleux, R., Mattarella, M., & Neri, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00304 · Cited by 92
Yasunaga, M., Manabe, S., Tarin, D., & Matsumura, Y. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200158j · Cited by 84
Joubert, N., Denevault‐Sabourin, C., Bryden, F., & Viaud‐Massuard, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.049 · Cited by 84
Self-citationProcesses for Constructing Homogeneous Antibody Drug Conjugates
Jackson, D. Y. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00067 · Cited by 77
New concept of cytotoxic immunoconjugate therapy targeting cancer‐induced fibrin clots
Yasunaga, M., Manabe, S., & Matsumura, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01954.x · Cited by 75
Albrecht, H., Burke, P. A., Natarajan, A., Xiong, C.-Y., Kalicinsky, M., DeNardo, G. L., & DeNardo, S. J. (2003) · Bioconjugate Chemistry · doi:10.1021/bc030018+ · Cited by 72
Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate
Lim, R. K. V., Yu, S., Cheng, B., Li, S., Kim, N., Cao, Y. J., Chi, V., Kim, J. Y., Chatterjee, A. K., Schultz, P. G., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00203 · Cited by 70
Emerging formats for next-generation antibody drug conjugates
Deonarain, M. P., Yahioglu, G., Stamati, I., & Marklew, J. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1025049 · Cited by 67
Jones, M. W., Strickland, R. A., Schumacher, F. F., Caddick, S., Baker, J. R., Gibson, M. I., & Haddleton, D. M. (2012) · Chemical Communications · doi:10.1039/c2cc30259d · Cited by 66
Carlson, J., Nooruddin, Z. I., Rusthoven, C. G., ELIAS, A. D., Borges, V. F., Diamond, J. R., Kavanagh, B. D., & Kabos, P. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not329 · Cited by 65
You, Y., Xu, Z., & Chen, Y. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1435746 · Cited by 65
Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
Gébleux, R., Wulhfard, S., Casi, G., & Neri, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0480 · Cited by 61
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
Brandish, P. E., Palmieri, A., Antonenko, S. V., Beaumont, M., Benso, L., Cancilla, M. T., Cheng, M. M., Fayadat‐Dilman, L., Feng, G., Figueroa, I., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00312 · Cited by 60
Goss, G. D., Vokes, E. E., Gordon, M. S., Gandhi, L., Papadopoulos, K. P., Rasco, D. W., Fischer, J. S., Chu, K. L., Ames, W., Mittapalli, R. K., et al. (2018) · Cancer · doi:10.1002/cncr.31304 · Cited by 59
Antibody-drug conjugates for non-oncological indications
Liu, R., Wang, R. E., & Wang, F. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1161753 · Cited by 56
Risks and untoward toxicities of antibody-based immunoconjugates
Litvak-Greenfeld, D., & Benhar, I. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.013 · Cited by 55
Bryden, F., Martin, C., Letast, S., et al. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02780j · Cited by 54
Bartlett, N. L., Sharman, J. P., Oki, Y., et al. (2013) · Blood · doi:10.1182/blood.v122.21.848.848 · Cited by 49
Widdison, W. C., Ponte, J. F., Coccia, J. A., Lanieri, L., Setiady, Y. Y., Dong, L., Skaletskaya, A., Hong, E., Wu, R., Qiu, Q., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00430 · Cited by 40
Noninternalizing Targeted Cytotoxics for Cancer Therapy
Casi, G., & Neri, D. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500798y · Cited by 36
Brachet, G., Respaud, R., Arnoult, C., Henriquet, C., Dhommée, C., Viaud‐Massuard, M., Heuzé‐Vourc'h, N., Joubert, N., Pugnière, M., & Gouilleux‐Gruart, V. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00082 · Cited by 33
Self-citationProspects and progress of antibody-drug conjugates in solid tumor therapies
Govindan, S. V., Sharkey, R. M., & Goldenberg, D. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1173203 · Cited by 33
Sauveur, J., Matera, E., Chettab, K., Valet, P., Guitton, J., Savina, A., & Dumontet, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24975 · Cited by 31
Self-citationAubrey, N., Allard-Vannier, É., Martin, C., Bryden, F., Letast, S., Colas, C., Lakhrif, Z., Collinet, N., Dimier‐Poisson, I., Chourpa, I., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00668 · Cited by 31
Self-citationDrug Trafficking into Macrophages via the Endocytotic Receptor CD163
Graversen, J. H., & Moestrup, S. K. (2015) · Membranes · doi:10.3390/membranes5020228 · Cited by 28
Martin, C., Kizlik‐Masson, C., Pèlegrin, A., Watier, H., Viaud‐Massuard, M., & Joubert, N. (2017) · mAbs · doi:10.1080/19420862.2017.1412130 · Cited by 27
Self-citationSandall, S. L., McCormick, R. S., Miyamoto, J. B., Biechele, T. L., Law, C., & Lewis, T. S. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-946 · Cited by 13
Komarnitsky, P. B., Lee, H., Shah, M., Wong, S. L., Gauthier, S., Dziubinski, J., Osbaugh, S., & Zhang, F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps8583 · Cited by 12
Les immunoconjugués en oncologie
Beck, A., Dumontet, C., & Joubert, N. (2019) · médecine/sciences · doi:10.1051/medsci/2019228 · Cited by 12
Self-citationLes immuno-conjugués en oncologie: Les raisons du succès récent d’une approche ancienne
Beck, A., Dumontet, C., & Joubert, N. (2019) · médecine/sciences · doi:10.1051/medsci/2019227 · Cited by 8
Self-citationMiller, M. L., Fishkin, N. E., Li, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b126 · Cited by 6
Antibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer
Denevault‐Sabourin, C., Bryden, F., Viaud‐Massuard, M., & Joubert, N. (2019) · doi:10.1002/9783527814695.ch3 · Cited by 6
Self-citationHardt, W. (2015) · Nature · doi:10.1038/nature15647 · Cited by 5
Antibody–drug conjugates: historical developments and mechanisms of action
Joubert, N., & Viaud‐Massuard, M. (2015) · doi:10.4155/fseb2013.14.27 · Cited by 3
Self-citation
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Self-citationEvolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00214-y · Cited by 80
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Singh, S., Serwer, L., DuPage, A., Elkins, K., Chauhan, N., Ravn, M., Buchanan, F., Wang, L., Krimm, M., Wong, K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0193 · Cited by 41
Metadata
- Authors
- Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-09-14
- Volume
- 13
- Issue
- 9
- Pages
- 245
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3085146133
- Cited by
- 366
- References
- 113
- FWCI
- 25.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.